{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T11:28:00Z","timestamp":1791199680859,"version":"4.2.0"},"reference-count":55,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T00:00:00Z","timestamp":1329782400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0031208","type":"journal-article","created":{"date-parts":[[2012,2,21]],"date-time":"2012-02-21T22:48:42Z","timestamp":1329864522000},"page":"e31208","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":141,"title":["Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors"],"prefix":"10.1371","volume":"7","clinical-trial-number":[{"clinical-trial-number":"nct01095055","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Susanne H.","family":"Sheehy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J. A.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean C.","family":"Elias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumi","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine A.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Geraldine A.","family":"O'Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenella D.","family":"Halstead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie J.","family":"Ewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabitha","family":"Mahungu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra J.","family":"Spencer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutoyo","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian D.","family":"Poulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D. J.","family":"Dicks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick J.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Berrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Moyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Colloca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Cortese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Gantlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carole A.","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison M.","family":"Lawrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Doherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Nicosia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian V. S.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon J.","family":"Draper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,2,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1016\/S0140-6736(10)61551-6","article-title":"Malaria elimination: worthy, challenging, and just possible.","volume":"376","author":"P Das","year":"2010","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/ni.f.205","article-title":"Immunity to malaria: more questions than answers.","volume":"9","author":"J Langhorne","year":"2008","journal-title":"Nat Immunol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1179\/136485910X12647085215534","article-title":"Blood-stage malaria vaccines - recent progress and future challenges.","volume":"104","author":"AL Goodman","year":"2010","journal-title":"Ann Trop Med Parasitol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1056\/NEJMc1100670","article-title":"Protection against malaria by MSP3 candidate vaccine.","volume":"365","author":"SB Sirima","year":"2011","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"e22273","DOI":"10.1371\/journal.pone.0022273","article-title":"Virosome-formulated Plasmodium falciparum AMA-1 & CSP derived peptides as malaria vaccine: randomized phase 1b trial in semi-immune adults & children.","volume":"6","author":"PG Cech","year":"2011","journal-title":"PLoS One"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJMoa1008115","article-title":"A field trial to assess a blood-stage malaria vaccine.","volume":"365","author":"MA Thera","year":"2011","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"e5254","DOI":"10.1371\/journal.pone.0005254","article-title":"Phase 1\/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system AS01B or AS02A.","volume":"4","author":"MD Spring","year":"2009","journal-title":"PLoS ONE"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.4161\/hv.6.8.11446","article-title":"Blood stage vaccines for Plasmodium falciparum: Current status and the way forward.","volume":"6","author":"RD Ellis","year":"2010","journal-title":"Hum Vaccin"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nm0111-49","article-title":"Defying malaria: Arming T cells to halt malaria.","volume":"17","author":"MF Good","year":"2011","journal-title":"Nat Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1146\/annurev.immunol.23.021704.115638","article-title":"Development and regulation of cell-mediated immune responses to the blood stages of malaria: implications for vaccine research.","volume":"23","author":"MF Good","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"4399","DOI":"10.1128\/IAI.68.8.4399-4406.2000","article-title":"Central role of endogenous gamma interferon in protective immunity against blood-stage Plasmodium chabaudi AS infection.","volume":"68","author":"Z Su","year":"2000","journal-title":"Infect Immun"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"6236","DOI":"10.4049\/jimmunol.166.10.6236","article-title":"A critical role of Fc receptor-mediated antibody-dependent phagocytosis in the host resistance to blood-stage Plasmodium berghei XAT infection.","volume":"166","author":"T Yoneto","year":"2001","journal-title":"J Immunol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"e9871","DOI":"10.1371\/journal.pone.0009871","article-title":"Clinical protection from falciparum malaria correlates with neutrophil respiratory bursts induced by merozoites opsonized with human serum antibodies.","volume":"5","author":"C Joos","year":"2010","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1084\/jem.172.6.1633","article-title":"Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes.","volume":"172","author":"H Bouharoun-Tayoun","year":"1990","journal-title":"J Exp Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.chom.2008.12.004","article-title":"Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria.","volume":"5","author":"SJ Draper","year":"2009","journal-title":"Cell Host Microbe"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"6075","DOI":"10.1128\/IAI.70.11.6075-6082.2002","article-title":"Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii.","volume":"70","author":"Y Kawabata","year":"2002","journal-title":"Infect Immun"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"8552","DOI":"10.4049\/jimmunol.181.12.8552","article-title":"Vaccination with live Plasmodium yoelii blood stage parasites under chloroquine cover induces cross-stage immunity against malaria liver stage.","volume":"181","author":"E Belnoue","year":"2008","journal-title":"J Immunol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"78","DOI":"10.4161\/hv.6.1.10116","article-title":"Prime-boost vectored malaria vaccines: progress and prospects.","volume":"6","author":"AVS Hill","year":"2010","journal-title":"Hum Vaccin"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"e20977","DOI":"10.1371\/journal.pone.0020977","article-title":"Transgene Optimization, Immunogenicity and In Vitro Efficacy of Viral Vectored Vaccines Expressing Two Alleles of Plasmodium falciparum AMA1.","volume":"6","author":"S Biswas","year":"2011","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.4049\/jimmunol.1001760","article-title":"Enhancing blood-stage malaria subunit vaccine immunogenicity in rhesus macaques by combining adenovirus, poxvirus, and protein-in-adjuvant vaccines.","volume":"185","author":"SJ Draper","year":"2010","journal-title":"J Immunol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pt.2007.12.002","article-title":"Apical membrane antigen 1: a malaria vaccine candidate in review.","volume":"24","author":"EJ Remarque","year":"2008","journal-title":"Trends Parasitol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"2ra5","DOI":"10.1126\/scitranslmed.3000257","article-title":"Extreme polymorphism in a vaccine antigen and risk of clinical malaria: implications for vaccine development.","volume":"1","author":"SL Takala","year":"2009","journal-title":"Sci Transl Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1128\/IAI.64.3.1054-1059.1996","article-title":"Identification of T-cell determinants in natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in an adult population exposed to malaria.","volume":"64","author":"AA Lal","year":"1996","journal-title":"Infect Immun"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4269\/ajtmh.2001.65.100","article-title":"Longitudinal study of natural immune responses to the Plasmodium falciparum apical membrane antigen (AMA-1) in a holoendemic region of malaria in western Kenya: Asembo Bay Cohort Project VIII.","volume":"65","author":"V Udhayakumar","year":"2001","journal-title":"Am J Trop Med Hyg"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.1016\/j.vaccine.2010.02.024","article-title":"Adenovectors induce functional antibodies capable of potent inhibition of blood stage malaria parasite growth.","volume":"28","author":"JT Bruder","year":"2010","journal-title":"Vaccine"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/1475-2875-9-241","article-title":"Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein.","volume":"9","author":"M Sedegah","year":"2010","journal-title":"Malar J"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"e24586","DOI":"10.1371\/journal.pone.0024586","article-title":"Adenovirus 5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part A: Safety and Immunogenicity in Seronegative Adults.","volume":"6","author":"M Sedegah","year":"2011","journal-title":"PLoS One"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer.","volume":"8","author":"SJ Draper","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/COH.0b013e32833cfe4c","article-title":"Novel adenovirus vector-based vaccines for HIV-1.","volume":"5","author":"DH Barouch","year":"2010","journal-title":"Curr Opin HIV AIDS"},{"key":"ref30","article-title":"Phase Ia Clinical Evaluation of the Plasmodium falciparum Blood-stage Antigen MSP1 in ChAd63 and MVA Vaccine Vectors.","author":"SH Sheehy","year":"2011","journal-title":"Mol Ther"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"12488","DOI":"10.1073\/pnas.0701464104","article-title":"Structural basis of antigenic escape of a malaria vaccine candidate.","volume":"104","author":"S Dutta","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref32","article-title":"A human Phase I\/IIa malaria challenge trial of a polyprotein malaria vaccine.","author":"DW Porter","year":"2011","journal-title":"Vaccine"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"6948","DOI":"10.1128\/IAI.70.12.6948-6960.2002","article-title":"In vitro studies with recombinant Plasmodium falciparum apical membrane antigen 1 (AMA1): production and activity of an AMA1 vaccine and generation of a multiallelic response.","volume":"70","author":"MC Kennedy","year":"2002","journal-title":"Infect Immun"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1002\/cyto.a.21015","article-title":"SPICE: exploration and analysis of post-cytometric complex multivariate datasets.","volume":"79","author":"M Roederer","year":"2011","journal-title":"Cytometry A"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.vaccine.2007.10.064","article-title":"Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines.","volume":"26","author":"K Miura","year":"2008","journal-title":"Vaccine"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1128\/CVI.00042-09","article-title":"Anti-apical-membrane-antigen-1 antibody is more effective than anti-42-kilodalton-merozoite-surface-protein-1 antibody in inhibiting plasmodium falciparum growth, as determined by the in vitro growth inhibition assay.","volume":"16","author":"K Miura","year":"2009","journal-title":"Clin Vaccine Immunol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1128\/JVI.80.4.1688-1699.2006","article-title":"A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques.","volume":"80","author":"S Capone","year":"2006","journal-title":"J Virol"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1016\/j.vaccine.2009.03.080","article-title":"Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan Children, in the context of vaccine vector efficacy.","volume":"27","author":"M Dudareva","year":"2009","journal-title":"Vaccine"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"2706","DOI":"10.1128\/IAI.74.5.2706-2716.2006","article-title":"Safety, immunogenicity, and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein.","volume":"74","author":"M Walther","year":"2006","journal-title":"Infect Immun"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1016\/j.vaccine.2010.12.104","article-title":"A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.","volume":"29","author":"MC Keefer","year":"2011","journal-title":"Vaccine"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"7167","DOI":"10.1016\/j.vaccine.2010.08.068","article-title":"Tailoring subunit vaccine immunogenicity: Maximizing antibody and T cell responses by using combinations of adenovirus, poxvirus and protein-adjuvant vaccines against Plasmodium falciparum MSP1.","volume":"28","author":"AD Douglas","year":"2010","journal-title":"Vaccine"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"4601","DOI":"10.1128\/IAI.00315-10","article-title":"New candidate vaccines against blood-stage Plasmodium falciparum malaria: prime-boost immunization regimens incorporating human and simian adenoviral vectors and poxviral vectors expressing an optimized antigen based on merozoite surface protein 1.","volume":"78","author":"AL Goodman","year":"2010","journal-title":"Infect Immun"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1073\/pnas.0406381102","article-title":"Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.","volume":"102","author":"DP Webster","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1016\/j.vaccine.2009.01.097","article-title":"Cell-mediated immunity elicited by the blood stage malaria vaccine apical membrane antigen 1 in Malian adults: results of a Phase I randomized trial.","volume":"27","author":"KE Lyke","year":"2009","journal-title":"Vaccine"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"e22271","DOI":"10.1371\/journal.pone.0022271","article-title":"Impact on Malaria Parasite Multiplication Rates in Infected Volunteers of the Protein-in-Adjuvant Vaccine AMA1-C1\/Alhydrogel+CPG 7909.","volume":"6","author":"CJ Duncan","year":"2011","journal-title":"PLoS One"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1128\/IAI.73.6.3677-3685.2005","article-title":"Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falciparum malaria.","volume":"73","author":"EM Malkin","year":"2005","journal-title":"Infect Immun"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1016\/j.vaccine.2009.12.049","article-title":"Phase 1 safety and immunogenicity trial of the Plasmodium falciparum blood-stage malaria vaccine AMA1-C1\/ISA 720 in Australian adults.","volume":"28","author":"MA Pierce","year":"2010","journal-title":"Vaccine"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"e2940","DOI":"10.1371\/journal.pone.0002940","article-title":"Phase 1 trial of AMA1-C1\/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria.","volume":"3","author":"GE Mullen","year":"2008","journal-title":"PLoS ONE"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"4104","DOI":"10.1016\/j.vaccine.2009.04.077","article-title":"A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1\/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.","volume":"27","author":"RD Ellis","year":"2009","journal-title":"Vaccine"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"7881","DOI":"10.1016\/j.vaccine.2010.09.079","article-title":"Comparison of T cell immune responses induced by vectored HIV vaccines in non-human primates and humans.","volume":"28","author":"AJ Bett","year":"2010","journal-title":"Vaccine"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"e25868","DOI":"10.1371\/journal.pone.0025868","article-title":"Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component.","volume":"6","author":"C Tamminga","year":"2011","journal-title":"PLoS One"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1038\/nm.1850","article-title":"Effective induction of high-titer antibodies by viral vector vaccines.","volume":"14","author":"SJ Draper","year":"2008","journal-title":"Nat Med"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1074\/jbc.M311331200","article-title":"A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites.","volume":"279","author":"O Silvie","year":"2004","journal-title":"J Biol Chem"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"e8110","DOI":"10.1371\/journal.pone.0008110","article-title":"Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity.","volume":"4","author":"KA Kusi","year":"2009","journal-title":"PLoS One"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.4049\/jimmunol.1101004","article-title":"The requirement for potent adjuvants to enhance the immunogenicity and protective efficacy of protein vaccines can be overcome by prior immunization with a recombinant adenovirus.","volume":"187","author":"SC de Cassan","year":"2011","journal-title":"J Immunol"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0031208","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T20:47:53Z","timestamp":1593722873000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0031208"}},"subtitle":[],"editor":[{"given":"Denise L.","family":"Doolan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,2,21]]},"references-count":55,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,2,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0031208","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,21]]}}}